Forward Looking Statements

Certain of the statements in this press release are forward looking, such as those, among others, relating to the potential effectiveness of folate-targeted therapies and the ability to determine the FR expression status of patients. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Stephanie Ascher         Stern Investor Relations, Inc.         (212) 362-1200         stephanie@sternir.com                  Martina Schwarzkopf, Ph.D.         Russo Partners         (212) 845-4292         martina.schwarzkopf@russopartnersllc.com                  Tony Russo, Ph.D.         Russo Partners         (212) 845-4251         tony.russo@russopartnersllc.com

If you liked this article you might like

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock

4 Biotech Stocks Under $10 to Trade for Breakouts

Why Endocyte (ECYT) Stock Is Declining Today